



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of DEBINSKI et al.

Serial No.: 10/075,499

Examiner:

1634
#4
CD/02

Date Filed: February 12, 2002

Group:

SEP 03 2002

TECH CENTER 1600/2900

For: FRA-1 EXPRESSION IN BRAIN CANCER

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on September 25, 2002



Reg. No. 42,730

Stanley A. Kim, Ph.D., Esq.

TRANSMITTAL LETTER

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Please find enclosed for filing the following:

- Information Disclosure Statement, with PTO-1449, and references; and
 1 postcard.

Although no fee is believed due, please charge any underpayment to Deposit Account No. 50-0951. This letter is submitted in duplicate.


Respectfully submitted,

AKERMAN SENTERFITT

Dated: September 25, 2002

Docket No. 6460-40


Stanley A. Kim, Ph.D., Esq.
Registration No. 42,730
222 Lakeview Avenue, Suite 400
P.O. Box 3188
West Palm Beach, FL 33402-3188
Tel: 561-653-5000



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Application of DEBINSKI et al.

Serial No.: 10/075,499

Examiner:

Date Filed: February 12, 2002

Group:

For: FRA-1 EXPRESSION IN BRAIN CANCER

RECEIVED

SEP 03 2002

TECH CENTER 1600/2900

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231, on September 25, 2002.

Reg. No. 42,730

Stanley A. Kim, Ph.D., Esq.

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Dear Sir:

Pursuant to the Duty to Disclose under 37 CFR 1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed.

The claimed invention is believed patentable over the disclosures enclosed. This citation is intended to give the Examiner an opportunity to make an independent evaluation. No representations are made regarding these materials.

Respectfully submitted,

AKERMAN SENTERFITT

Stanley A. Kim, Ph.D., Esq.

Registration No. 42,730

222 Lakeview Avenue, Suite 400

P.O. Box 3188

West Palm Beach, FL 33402-3188

Tel: 561-653-5000

Dated: September 25, 2002



Sheet 1 of 1

Form PTO-1449
(Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
6460-40

APPLICATION NO.
10/075,499

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT
Debinski et al.

FILING DATE
February 12, 2002

GROUP

U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		6,124,133	9/26/00	Taylor et al.			
							RECEIVED
							SEP 03 2002
							TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Bhattacharya et al., "Regulation of the Urokinase-type Plasminogen Activator Receptor Gene in Different Grades of Human Glioma Cell Lines," Clinical Cancer Research, 7: 267-276, 2001
		Won et al., "Stimulation of astrocyte-enriched culture with arachidonic acid increases proenkephalin mRNA: involvement of proto-oncogene and mitogen activated protein kinases," Molecular Brain Research, 76: 396-406, 2000
		Kustikova et al., "Fra-1 Induces Morphological Transformation and Increases In Vitro Invasiveness and Motility of Epithelioid Adenocarcinoma Cells," Molecular and Cellular Biology, 18: 7095-7105, 1998
		Chiappetta et al., "FRA-1 Expression in Hyperplastic and Neoplastic Thyroid Diseases ¹ ," Clinical Cancer Research, 6: 4300-4307, 2000
		Debinski et al., "VEGF-D is an X-linked/AP-1 Regulated Putative Onco-angiogen in Human Glioblastoma Multiforme," Molecular Medicine 7: 598-608, 2001

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.